| Oral Targeted Agent Recentin™ Active in Renal Cell Carcinoma - Cancer Consultants |
|
|
Cancer ConsultantsFinal results of a phase II randomised study of cediranib (Recentin™) in patients with advanced renal cell carcinoma (RCC). European Journal of Cancer ... read more |